Immutep Announces First Participant Dosed In Phase I Study Of IMP761
Immutep Announces First Participant Dosed In Phase I Study Of IMP761
- IMP761 is designed to enhance the "brake" function of LAG-3 on T cells to restore balance to the immune system and address the underlying cause of many autoimmune diseases
- Safety data from this first-in-human study anticipated by year-end and pharmacokinetics and pharmacodynamics data in first half CY2025
- IMP761旨在增強t細胞上的LAG-3的「剎車」功能，以恢復免疫系統的平衡，解決許多自身免疫性疾病的根本原因。
- 第一例人體試驗的安全數據預計於年底公佈，藥物動力學和藥物動力學數據將在2025年上半年公佈。
SYDNEY, AUSTRALIA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that the first participant has been successfully dosed in the first-in-human Phase I trial of IMP761. This first-in-class agonist LAG-3 antibody is designed to restore balance to the immune system by enhancing the "brake" function of LAG-3 to silence dysregulated self-antigen-specific memory T cells that cause many autoimmune diseases.
澳洲悉尼，2024年8月14日（環球新聞社） - 生物技術公司Immutep Limited（（ASX：IMM，納斯達克：IMMP）（「Immutep」或「公司」）宣佈，在IMP761的首個一期人體試驗中成功給第一名參與者注射了這種首創性LAG-3激動劑抗體，旨在通過增強LAG-3的「剎車」功能來平衡免疫系統，使失調的特異性自身抗原記憶t細胞沉默，以治療許多自身免疫疾病。
